HIV-1 drug resistance has tremendous impact on antiretroviral treatment success and overall health care costs. For clinical genomics assays assessing HIV-1 drug resistance, robust reference materials are critical to ensure the accurate detection of relevant mutations which ultimately affect treatment outcomes.
The ideal reference material should include a wide range of clinically relevant drug resistance mutations, mimic true viral genome complexity, assess full process variability, and be non-infectious for safe handling. Seraseq HIV-1 Drug Resistance and Tropism Reference Material v2, based on SeraCare’s patent-pending AccuPlex recombinant virus technology, meets these requirements with an innovative product.
Key features include:
49 clinically relevant mutations in a single sample to expedite new assay development or validation
Variants cover Gag, Protease (PRO), Reverse Transcriptase (RT) and Integrase (INT) regions of HIV-1 genome
Assess assay performance across entire workflow from extraction through analysis with fully extractable material in mammalian RNA viral protein coat
Target mutation frequency of 40% to confidently assess Sanger sequencing assays
Product is non-infectious and designed with non-replicative recombinant RNA virus
Target concentration of 50,000 copies/mL in defibrinated human plasma
For research use only. Not for use in diagnostic procedures.
Seraseq HIV-1 Drug Resistance and Tropism Reference Materials v2 (MF40)